Zacks upgraded Fractyl Health (GUTS) to a Zacks Rank #2 (Buy), signaling increased optimism about the company’s earnings prospects. The rating change could lift the small-cap biotech’s shares in the near term as sentiment-driven flows push the stock a few percent higher.
Zacks upgraded Fractyl Health (GUTS) to a Zacks Rank #2 (Buy), signaling increased optimism about the company’s earnings prospects. The rating change could lift the small-cap biotech’s shares in the near term as sentiment-driven flows push the stock a few percent higher.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
